{"release":"wpf-claim-checks","version":"1.6.0","checkedOn":"2026-11-15","verificationLabel":"AI-assisted source verification","humanReview":"none recorded","claim":{"id":"research-use-only-label-product","claimWording":"A product labelled “research use only” is not a drug.","wordingKind":"representative","quoted":null,"title":"A “research use only” label and the products in one FDA warning letter","peptides":["retatrutide","cagrilintide","semaglutide","mazdutide","survodutide"],"aliases":["RETA","LY3437943","research chemical","RUO","Xcel Research","CagriLean","SEMA"],"topics":["regulatory"],"verdict":"contradicted_by_evidence","plainAnswer":"For the seven products in FDA's warning letter to Xcel Research LLC, a “for research use only” label did not make them non-drugs. FDA said the seller's own website claims showed the products were intended as drugs for human use, and that they were unapproved new drugs with no approved application in effect. The letter does not say whether using such a product is acceptable or safe, and this check does not either.","scope":{"population":"Seven products sold by one US vendor, Xcel Research LLC: “RETA” (retatrutide), “CagriLean” (cagrilintide and semaglutide), cagrilintide, mazdutide, “SEMA” (semaglutide), survodutide and sermorelin","design":"A regulatory enforcement letter (FDA Warning Letter), not a court ruling or a scientific study","boundary":"FDA's stated position about the named vendor and the seven named products on 10 December 2024 (website reviewed in October 2024). It says nothing about any other seller or product, nothing about whether any product works or is safe, and nothing about whether using a product is acceptable. The earlier wording of this check (1.0.0 to 1.3.0) also said “and it is fine to use on yourself”; that clause is removed because no source read addresses it."},"strongest":[{"label":"FDA Warning Letter to Xcel Research LLC (694608), 10 December 2024","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024","kind":"Regulatory document","population":"Products named by FDA: RETA (retatrutide), CagriLean (cagrilintide and semaglutide), CAGRILINTIDE, MAZDUTIDE, SEMA (semaglutide), SURVODUTIDE and SERMORELIN, offered for sale in the United States on the firm's website","design":"FDA CDER warning letter citing sections 505(a) and 301(d) of the FD&C Act, the definition of a drug in section 201(g)(1) and of a new drug in section 201(p)","locator":"Opening paragraph: the products carry the statements \"FOR RESEARCH USE ONLY\" and \"NOT INTENDED FOR HUMAN USE\", yet \"evidence obtained from your website establishes that your products are intended to be drugs for human use\". Second sentence of the same paragraph: the products are drugs \"because they are intended to prevent, treat, or cure disease conditions and/or affect the structure or function of the body\". Examples of website claims FDA cited as evidence of intended use (section beginning \"Examples of claims observed on your website\"): RETA \"exhibits potential for weight management by regulating appetite and metabolism\" and \"Cardiovascular Protection\"; SEMA \"Weight Loss and Appetite Suppression\"; SERMORELIN \"Improved Metabolism and Fat Loss\". Closing paragraphs: the products are not generally recognized as safe and effective for those uses, so they are new drugs; \"No FDA-approved applications pursuant to section 505 of the FD&C Act ... are in effect for these products\"; the firm is asked to respond in writing within fifteen working days. Page footer: content current as of 12/17/2024."}],"uncertain":["A warning letter states FDA's position. It is not a court finding, and WPF did not read the firm's response or any later action.","WPF read one letter, about one vendor and seven products. Other letters exist (the same pattern was reported for other vendors), but they were not read here and are not part of this verdict.","The letter does not address whether it is acceptable or safe to use such a product, so this check does not assess that.","Retatrutide itself is an investigational drug in clinical trials; the letter's point is about the vendor's unapproved sales, not about the drug's trial results."],"wouldChange":["A court decision, or an FDA rule or guidance, that treats a research-use-only label as determining drug status regardless of marketing.","Withdrawal or revision of the letter on FDA's website."],"gaps":["WPF did not read the vendor's response, any enforcement that followed, or the FDA letters to other peptide sellers; a general claim about all research-use-only peptides is therefore not assessed."],"searchScope":{"searchedOn":"2026-11-15","sources":["FDA.gov warning letter page (read in full, 2026-11-15)","Web search to locate FDA warning letters about research-use-only peptides"],"queries":["Web search: FDA warning letter \"research use only\" peptides unapproved new drug"],"found":"Several FDA warning letters to peptide vendors were listed; one (Xcel Research LLC, 2024-12-10) was read in full and is the only one this verdict rests on.","notSearched":["The other FDA letters returned by the search","Court records","FDA guidance on research-use-only labelling for non-diagnostic products"]},"regulatory":{"product":"Seven products sold by Xcel Research LLC, including “RETA” (retatrutide)","indication":"None. FDA identifies each as an unapproved new drug; no FDA-approved application is in effect for any of them.","jurisdiction":"United States (FDA, Center for Drug Evaluation and Research)","decisionType":"Warning letter (enforcement correspondence). Not an approval, a denial or a court judgment.","decisionDate":"2024-12-10","officialSource":{"label":"FDA Warning Letter, Xcel Research LLC (694608), 10 Dec 2024","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024"}},"checkedOn":"2026-11-15","links":{"profiles":["/directory/retatrutide","/directory/cagrilintide","/directory/semaglutide","/directory/mazdutide","/directory/survodutide"],"films":[],"flagship":["https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#retatrutide-phase2-weight-48w"],"journeys":[],"teaching":[],"changes":[]},"extends1_0_0":false},"sha256":"8a31f4ea4e2019d47012650e7f6a82d2798d59602465a447be33da6c0ccb40b6"}